Stephen X Skapek

List of Publications by Year
in descending order

Version: 2024-02-01

39 papers	2,514 citations	394421 19 h-index	345221 36 g-index
40 all docs	40 docs citations	40 times ranked	3906 citing authors

#	Article	IF	Citations
1	HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma. Oncogene, 2021, 40, 578-591.	5.9	20
2	Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. British Journal of Cancer, 2021, 124, 1637-1646.	6.4	12
3	Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Childrenâ€™s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. Journal of Clinical Medicine, 2021, 10, 1416.	2.4	11
4	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	1.6	101
5	Bayesian Modeling Identifies PLAG1 as a Key Regulator of Proliferation and Survival in Rhabdomyosarcoma Cells. Molecular Cancer Research, 2020, 18, 364-374.	3.4	9
6	A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncology, The, 2020, 21, 145-161.	10.7	89
7	Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts. Pediatric Blood and Cancer, 2020, 67, e28639.	1.5	2
8	Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Childrenâ€™s Oncology Group. Scientific Reports, 2020, 10, 12318.	3.3	28
9	Development of a Data Model and Data Commons for Germ Cell Tumors. JCO Clinical Cancer Informatics, 2020, 4, 555-566.	2.1	6
10	Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. Cancer Medicine, 2019, 8, 6437-6448.	2.8	90
11	Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib. Journal of Physical Education and Sports Management, 2019, 5, a004440.	1.2	12
12	Testis-specific Arf promoter expression in a transposase-aided BAC transgenic mouse model. Molecular Biology Reports, 2019, 46, 6243-6252.	2.3	0
13	Identification of De Novo Enhancers Activated by TGFÎ² to Drive Expression of CDKN2A and B in HeLa Cells. Molecular Cancer Research, 2019, 17, 1854-1866.	3.4	6
14	Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. Genes and Development, 2019, 33, 626-640.	5.9	27
15	Rhabdomyosarcoma. Nature Reviews Disease Primers, 2019, 5, 1.	30.5	619
16	Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusionâ€“negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2018, 124, 1973-1981.	4.1	14
17	Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group. Clinical Cancer Research, 2018, 24, 3888-3897.	7.0	11
18	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2018, 36, 2770-2777.	1.6	124

#	Article	IF	Citations
19	PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis. ELife, 2018, 7, .	6.0	39
20	Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes. Cell Reports, 2018, 24, 238-251.	6.4	25
21	Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26645.	1.5	82
22	The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 1557-1562.	1.5	7
23	Negative regulation of initial steps in skeletal myogenesis by mTOR and other kinases. Scientific Reports, 2016, 6, 20376.	3.3	5
24	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genetics, 2016, 209, 182-194.	0.4	38
25	Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Childrenâ€™s Oncology Group. Scientific Reports, 2016, 6, 33429.	3.3	1
26	Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Lowâ€Risk Clinical Features: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 634-639.	1.5	53
27	Clonality and Evolutionary History of Rhabdomyosarcoma. PLoS Genetics, 2015, 11, e1005075.	3.5	58
28	Clinical Application of Prognostic Gene Expression Signature in Fusion Geneâ€“Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2015, 21, 4733-4739.	7.0	21
29	Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nature Communications, 2015, 6, 8891.	12.8	126
30	Sarcomas. Pediatric Clinics of North America, 2015, 62, 179-200.	1.8	65
31	Isolation and characterization of mammalian cells expressing theArfpromoter during eye development. BioTechniques, 2014, 56, 239-49.	1.8	3
32	miR-34a is essential for p19Arf-driven cell cycle arrest. Cell Cycle, 2014, 13, 792-800.	2.6	17
33	Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. Cancer Discovery, 2014, 4, 216-231.	9.4	596
34	Odontogenic Myxoma of the Face: Mimicry of Cherubism. Journal of Oral and Maxillofacial Surgery, 2014, 72, 2186-2191.	1.2	10
35	Varied manifestations of persistent hyperplastic primary vitreous with graded somatic mosaic deletion of a single gene. Molecular Vision, 2014, 20, 215-30.	1.1	3
36	Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma. American Journal of Clinical Pathology, 2013, 140, 82-90.	0.7	74

#	Article	IF	Citations
37	Safety and efficacy of highâ€dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study. Pediatric Blood and Cancer, 2013, 60, 1108-1112.	1.5	106
38	Relationship of fusion protein status and outcome for children with intermediate-risk rhabdomyosarcoma: A Children's Oncology Group report.. Journal of Clinical Oncology, 2012, 30, 9535-9535.	1.6	3
39	Predictors of pediatric and adult fibrosarcoma survival: Analyses of the Surveillance, Epidemiology, and End Results (SEER) program, 1973-2008.. Journal of Clinical Oncology, 2012, 30, 1576-1576.	1.6	0